| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
We have proposed that the enhancement of interleukin (IL)-10 production in the intestinal macrophages has the potential to be a novel therapeutic mechanism for maintaining the remission of inflammatory bowel disease (IBD) and found berberine as a candidate compound for IL-10 enhancer. In the present study, we developed a useful experimental animal model to evaluate the relapse phase of IBD and investigated the effect of berberine on this model. Berberine significantly attenuated colitis symptoms during the relapse phase of IBD relapse model. Furthermore, we detected fatty acid synthase (FAS) as a candidate target protein. FAS inhibitor suppressed the IL-10 production of macrophages enhanced by berberine in a concentration-dependent manner. This study suggests that FAS activators such as berberine may be useful in developing a novel therapeutic strategy aimed at preventing relapse in IBD.
|
